Phaseline

Companies › TwoStep Therapeutics

TwoStep Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Aug 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TS-104
Peptide-drug conjugate (PDC) delivering monomethyl auristatin E (MMAE) via integrin-target
ITGA, ITGBPhase 1NSCLC (Non-small Cell Lung Cancer)Aug 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07814248TS-104Phase 1NSCLC (Non-small Cell Lung Cancer)OncologyAug 2028

Targets

ITGA (1) ITGB (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.